STAAR Surgical Company (STAA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$27.17+7.95%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · STAA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Growing Adoption with Commercial Innovation We are focused on growing global ICL adoption to capitalize on the market opportunity that we outlined in our September report entitled The Future of Refra…
Stated in 4 of 4 supplied quarters. Management reported: “Key 2026 Operational Highlights: • Record first-quarter net sales of $93.5 million • Surpassed the milestone of 4 million ICLs sold globally • Return to growth in China, with distributor inventory at or below contractual levels • Strong launch of EVO+ ICL in China • Double-digit U.S. net sales growth with quarterly net sales surpassing $6 million • Return to profitability with improving margins 1 Exhibit 99.1 Business Update Our priority in 2026 is to return STAAR to consistent, profitable growth while maintaining disciplined execution.” “STAAR’s Board of Directors have engaged Egon Zehnder, a leading global executive search and leadership advisory firm, to conduct the search for STAAR’s next Chief Executive Officer.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Growing Adoption with Commercial Innovation We are focused on growing global ICL adoption to capitalize on the market opportunity that we outlined in our September report entitled The Future of Refra…”
“Progress Against Our Priorities Nearly six months ago, we set a clear agenda: Revenue Growth, Profit Expansion, and Innovation Acceleration.”
“Our focus remains on three core objectives: Revenue Growth — accelerating performance in key markets while expanding into new opportunities Profit Expansion — maintaining disciplined cost management,…”
“In 2026, with the merger question behind us, we believe we will see modest growth in in-market volume demand and expect net sales in China to increase due to rising average selling prices (ASPs) for…”
Delivering with Excellence with Operational Innovation We are focused on achieving advancements in manufacturing and supply chain management to support continued profit expansion.
Stated in 4 of 4 supplied quarters. Management reported: “As net sales grow, we expect disciplined spending to drive operating leverage and support a return to double-digit operating margins over time.” “Higher gross margins and disciplined expense management supported a meaningful improvement in our bottom line, and we remain focused on driving operating leverage as we scale.”
“Delivering with Excellence with Operational Innovation We are focused on achieving advancements in manufacturing and supply chain management to support continued profit expansion.”
“Profit Expansion and Operating Leverage We are committed to growing profitably by making smart investments where they matter while staying disciplined across our spending.”
“Our focus remains on three core objectives: Revenue Growth — accelerating performance in key markets while expanding into new opportunities Profit Expansion — maintaining disciplined cost management,…”
“Fourth Quarter 2025 Financial Overview • Net sales of $57.8 million, up 18.1% Y/Y • Net sales excluding China of $40.3 million, down 2.1% Y/Y • Gross margin at 75.7% vs. 64.7% Y/Y • Net loss of $(18.…”
Advance the Future of Vision, enabled by Product Innovation: Investing in R&D, clinical proof, and regulatory progress to expand beyond our core offering and bring meaningful new products to patients.
Stated in 3 of 4 supplied quarters. Management reported: “We have begun the clinical trial process for our next-generation presbyopia technologies, with first-in-human clinical trials for two products expected to begin patient enrollment in the next few months, subject to receipt of the remaining required regulatory authorizations.” “Focusing on the future, our R&D team and our Advanced Research group are preparing for first-in-human studies of next generation products.”
“Advance the Future of Vision, enabled by Product Innovation: Investing in R&D, clinical proof, and regulatory progress to expand beyond our core offering and bring meaningful new products to patients.”
“Our Future: From Product to Platform to Enterprise With respect to Innovation Acceleration, our early success with the launch of EVO+ in China is a great example of the impact that new products can m…”
“Our focus remains on three core objectives: Revenue Growth — accelerating performance in key markets while expanding into new opportunities Profit Expansion — maintaining disciplined cost management,…”
In addition, we are strengthening our supply chain planning and inventory management capabilities.
Stated in 3 of 4 supplied quarters. Management reported: “Additional efforts underway include targeted initiatives to improve manufacturing yields and expand capacity while maintaining the rigorous quality standards required to produce Collamer.” “We plan for our Nidau facility in 2026 to supply 100% of the EVO ICL and EVO+ ICL lenses we ship to China, without import tariffs.”
“In addition, we are strengthening our supply chain planning and inventory management capabilities.”
“As part of our focus on achieving our revenue growth goals, we are concurrently focused on continuously improving our production and supply chain efficiency to support our customers, partners and the…”
“Key 2026 Operational Highlights: • Record first-quarter net sales of $93.5 million • Surpassed the milestone of 4 million ICLs sold globally • Return to growth in China, with distributor inventory at…”
Continue cost reduction efforts, manage operating expenses prudently, and invest selectively to support growth and profitability.
Over the trailing year it converted -0.59x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
20 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.